Based on improving new product visibility, benefits from restructuring initiatives, and near-term volume boost from Medicare Part D supports our Attractive rating for the U.S. pharmaceutical sector.
-Jami Rubin
Select a background
More quotes by Jami Rubin
Popular Authors
A curated listing of popular authors.